Suppression of HSP27 increases the anti-tumor effects of quercetin in human leukemia U937 cells

Molecular Medicine Reports

Volumn 13, Issue 1, 2016, Pages 689-696

  Chen, Xi ^a   Dong, Xiu Shuai ^a   Gao, Hai Yan ^a   Jiang, Yong Fang ^a   Jin, Ying Lan ^a   Chang, Yu Ying ^a   Chen, Li Yan ^a   Wang, Jing Hua ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

AKT mammalian target of rapamycin; Heat shock protein 27; Leukemia; Quercetin

Indexed keywords

CYCLIN D1; HEAT SHOCK PROTEIN 27; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LENTIVIRUS VECTOR; MAMMALIAN TARGET OF RAPAMYCIN; NOTCH RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; QUERCETIN; SHORT HAIRPIN RNA; VASCULOTROPIN; ANTINEOPLASTIC AGENT; HSPB1 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INFILTRATION; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LEUKEMIA; PROTEIN EXPRESSION; U937 CELL LINE; WESTERN BLOTTING; CELL ADHESION; CELL CYCLE G1 PHASE; DRUG EFFECTS; GENE SILENCING; METABOLISM; PATHOLOGY; U-937 CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION; CELL PROLIFERATION; G1 PHASE; GENE KNOCKDOWN TECHNIQUES; HSP27 HEAT-SHOCK PROTEINS; HUMANS; LEUKEMIA; QUERCETIN; RNA, SMALL INTERFERING; U937 CELLS;

EID: 84954216638     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4600     Document Type: Article

References (63)

1. Kuttan G, Pratheeshkumar P, Manu KA and Kuttan R: Inhibition of tumor progression by naturally occurring terpenoids. Pharm Biol 49: 995-1007, 2011.
2. Pratheeshkumar P, Sreekala C, Zhang Z, Budhraja A, Ding S, Son YO, Wang X, Hitron A, Hyun-Jung K, Wang L, et al: Cancer prevention with promising natural products: Mechanisms of action and molecular targets. Anticancer Agents Med Chem 12: 1159-1184, 2012.
3. Larson AJ, Symons JD and Jalili T: Therapeutic potential of quercetin to decrease blood pressure: Review of efficacy and mechanisms. Adv Nutr 3: 39-46, 2012.
4. Okamoto T: Safety of quercetin for clinical application (Review). Int J Mol Med 16: 275-278, 2005.
5. Formica JV and Regelson W: Review of the biology of Quercetin and related bioflavonoids. Food Chem Toxicol 33: 1061-1080, 1995.
6. Lee JC, Kim J, Park JK, Chung GH and Jang YS: The antioxidant, rather than prooxidant, activities of quercetin on normal cells: Quercetin protects mouse thymocytes from glucose oxidase-mediated apoptosis. Exp Cell Res 291: 386-397, 2003.
7. Liesveld JL, Abboud CN, Lu C, McNair C, Menon A, Smith A, Rosell K and Rapoport AP: Flavonoid effects on normal and leukemic cells. Leuk Res 27: 517-527, 2003.
8. Cheng S, Gao N, Zhang Z, Chen G, Budhraja A, Ke Z, Son YO, Wang X, Luo J and Shi X: Quercetin induces tumor-selective apoptosis through downregulation of Mcl-1 and activation of Bax. Clin Cancer Res 16: 5679-5691, 2010.
9. Kang TB and Liang NC: Studies on the inhibitory effects of quercetin on the growth of HL-60 leukemia cells. Biochem Pharmacol 54: 1013-1018, 1997.
10. Román-Gómez J, Cordeu L, Agirre X, Jiménez-Velasco A, San José-Eneriz E, Garate L, Calasanz MJ, Heiniger A, Torres A and Prosper F: Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 109: 3462-3469, 2007.
11. Kimura A: Radiation associated leukemia and myelodysplastic syndrome. Nihon Rinsho 70: 431-435, 2012 (In Chinese).
12. Noshchenko AG, Bondar OY and Drozdova VD: Radiation-induced leukemia among children aged 0-5 years at the time of the Chernobyl accident. Int J Cancer 127: 412-426, 2010.
13. Malagoli C, Malavolti M, Costanzini S, Fabbri S, Tezzi S, Palazzi G, Arcolin E and Vinceti M: Increased incidence of childhood leukemia in urban areas: A population-based case-control study. Epidemiol Prev 39: 102-107, 2015.
14. Garcia-Perez J, López-Abente G, Gómez-Barroso D, Morales-Piga A, Romaguera EP, Tamayo I, Fernández-Navarro P and Ramis R: Childhood leukemia and residential proximity to industrial and urban sites. Environ Res 140: 542-553, 2015.
15. Zeeshan R, Sultan S, Irfan SM, Kakar J and Hameed MA: Clinico-hematological profile of patients with B-chronic lymphoid leukemia in Pakistan. Asian Pac J Cancer Prev 16: 793-796, 2015.
16. Khalafalla MM, Abdellatef E, Daffalla HM, et al: Antileukemia activity from root cultures of Vernonia amygdalina. J Med Plants Res 3: 556-562, 2009.
17. Bukau B and Horwich AL: The Hsp70 and Hsp60 chaperone machines. Cell 92: 351-366, 1998.
18. Polla BS, Kantengwa S, Gleich GJ, Kondo M, Reimert CM and Junod AF: Spontaneous heat shock protein synthesis by alveolar macrophages in interstitial lung disease associated with phagocytosis of eosinophils. Eur Respir J 6: 483-488, 1993.
19. Taba K, Kuramitsu Y, Ryozawa S, Yoshida K, Tanaka T, Maehara S, Maehara Y, Sakaida I and Nakamura K: Heat-shock protein 27 is phosphorylated in gemcitabine-resistant pancreatic cancer cells. Anticancer Res 30: 2539-2543, 2010.
20. Carper SW, Duffy JJ and Gerner EW: Heat shock proteins in thermotolerance and other cellular processes. Cancer Res 47: 5249-5255, 1987.
21. Ricci JE, Maulon L, Battaglione-Hofman V, Bertolotto C, Luciano F, Mari B, Hofman P and Auberger P: A Jurkat T cell variant resistant to death receptor-induced apoptosis. Correlation with heat shock protein (Hsp) 27 and 70 levels. Eur Cytokine Netw 12: 126-134, 2001.
22. Pandey P, Farber R, Nakazawa A, Kumar S, Bharti A, Nalin C, Weichselbaum R, Kufe D and Kharbanda S: Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3. Oncogene 19: 1975-1981, 2000.
23. Garrido C, Ottavi P, Fromentin A, Hammann A, Arrigo AP, Chauffert B and Mehlen P: HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res 57: 2661-2667, 1997.
24. Garrido C, Bruey JM, Fromentin A, Hammann A, Arrigo AP and Solary E: HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J 13: 2061-2070, 1999.
25. Piantelli M, Tatone D, Castrilli G, Savini F, Maggiano N, Larocca LM, Ranelletti FO and Natali PG: Quercetin and tamoxifen sensitize human melanoma cells to hyperthermia. Melanoma Res 11: 469-476, 2001.
26. Jakubowicz-Gil J, Rzymowska J and Gawron A: Quercetin, apoptosis, heat shock. Biochem Pharmacol 64: 1591-1595, 2002.
27. Chen SF, Nieh S, Jao SW, Liu CL, Wu CH, Chang YC, Yang CY and Lin YS: Quercetin suppresses drug-resistant spheres via the p38 MAPK-Hsp27 apoptotic pathway in oral cancer cells. PLoS One 7: e49275, 2012.
28. Zhou H and Huang S: Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr Protein Pept Sci 12: 30-42, 2011.
29. Efeyan A and Sabatini DM: mTOR and cancer: Many loops in one pathway. Curr Opin Cell Biol 22: 169-176, 2010.
30. Pratheeshkumar P, Budhraja A, Son YO, Wang X, Zhang Z, Ding S, Wang L, Hitron A, Lee JC, Xu M, et al: Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS One 7: e47516, 2012.
31. Bruning A: Inhibition of mTOR signaling by quercetin in cancer treatment and prevention. Anticancer Agents Med Chem 13: 1025-1031, 2013.
32. O'Callaghan-Sunol C, Gabai VL and Sherman MY: Hsp27 modulates p53 signaling and suppresses cellular senescence. Cancer Res 67: 11779-11788, 2007.
33. Niu G, Yin S, Xie S, Li Y, Nie D, Ma L, Wang X and Wu Y: Quercetin induces apoptosis by activating caspase-3 and regulating Bcl-2 and cyclooxygenase-2 pathways in human HL-60 cells. Acta Biochim Biophys Sin (Shanghai) 43: 30-37, 2011.
34. Mahbub AA, Le Maitre CL, Haywood-Small SL, McDougall GJ, Cross NA and Jordan-Mahy N: Differential effects of polyphenols on proliferation and apoptosis in human myeloid and lymphoid leukemia cell lines. Anticancer Agents Med Chem 13: 1601-1613, 2013.
35. Hansel DE, Platt E, Orloff M, Harwalker J, Sethu S, Hicks JL, De Marzo A, Steinle RE, Hsi ED, Theodorescu D, et al: Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol 176: 3062-3072, 2010.
36. Osorio LM, Jondal M and Aguilar-Santelises M: Regulation of B-CLL apoptosis through membrane receptors and Bcl-2 family proteins. Leuk Lymphoma 30: 247-256, 1998.
37. Podhorecka M, Halicka D, Klimek P, Kowal M, Chocholska S and Dmoszynska A: Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol 89: 1115-1124, 2010.
38. Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer 9: 153-166, 2009.
39. Evans T, Rosenthal ET, Youngblom J, Distel D and Hunt T: Cyclin: A protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell 33: 389-396, 1983.
40. Hwang A, Maity A, McKenna WG and Muschel RJ: Cell cycle-dependent regulation of the cyclin B1 promoter. J Biol Chem 270: 28419-28424, 1995.
41. Hartwell LH and Kastan MB: Cell cycle control and cancer. Science 266: 1821-1828, 1994.
42. Yuan J, Kramer A, Matthess Y, Yan R, Spänkuch B, Gätje R, Knecht R, Kaufmann M and Strebhardt K: Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo. Oncogene 25: 1753-1762, 2006.
43. Nakata Y, Shetzline S, Sakashita C, Kalota A, Rallapalli R, Rudnick SI, Zhang Y, Emerson SG and Gewirtz AM: c-Myb contributes to G2/M cell cycle transition in human hematopoietic cells by direct regulation of cyclin B1 expression. Mol Cell Biol 27: 2048-2058, 2007.
44. Donnellan R and Chetty R: Cyclin D1 and human neoplasia. Mol Pathol 51: 1-7, 1998.
45. Becker PS: Dependence of acute myeloid leukemia on adhesion within the bone marrow microenvironment. Scientific World Journal 2012: 856467, 2012.
46. Koukoulis GK, Patriarca C and Gould VE: Adhesion molecules and tumor metastasis. Hum Pathol 29: 889-892, 1998.
47. Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM and Dalton WS: Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 98: 1897-1903, 2001.
48. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 (Suppl 6): S15-S18, 2002.
49. Dai Y, Xu M, Wang Y, Pasha Z, Li T and Ashraf M: HIF-1alpha induced-VEGF overexpression in bone marrow stem cells protects cardiomyocytes against ischemia. J Mol Cell Cardiol 42: 1036-1044, 2007.
50. Sasabe E, Tatemoto Y, Li D, Yamamoto T and Osaki T: Mechanism of HIF-1alpha-dependent suppression of hypoxia-induced apoptosis in squamous cell carcinoma cells. Cancer Sci 96: 394-402, 2005.
51. Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, Liu KJ, Shi X and Jiang BH: G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 287: C281-C291, 2004.
52. Rong Y, Yang EB, Zhang K and Mack P: Quercetin-induced apoptosis in the monoblastoid cell line U937 in vitro and the regulation of heat shock proteins expression. Anticancer Res 20 (6B): 4339-4345, 2000.
53. Scambia G, Ranelletti FO, Panici PB, De Vincenzo R, Bonanno G, Ferrandina G, Piantelli M, Bussa S, Rumi C and Cianfriglia M: Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 34: 459-464, 1994.
54. Volate SR, Davenport DM, Muga SJ and Wargovich MJ: Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). Carcinogenesis 26: 1450-1456, 2005.
55. Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R, De Bont ES, De Moerloose B, Dworzak M, Gibson BE, et al: Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. J Clin Oncol 33: 2949-2962, 2015.
56. Katz AJ, Chia VM, Schoonen WM and Kelsh MA: Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. Cancer Causes Control 26: 1627-1642, 2015.
57. Gregoire, M, Ligeza-Poisson C, Juge-Morineau N, Spisek R: Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia. Vaccine 21: 791-794, 2003.
58. Schmidt T and Carmeliet P: Angiogenesis: A target in solid tumors, also in leukemia? Hematology Am Soc Hematol Educ Program 2011: 1-8, 2011.
59. Trujillo A, McGee C and Cogle CR: Angiogenesis in acute myeloid leukemia and opportunities for novel therapies. J Oncol 2012: 128608, 2012.
60. Kampen KR, Ter Elst A and de Bont ES: Vascular endothelial growth factor signaling in acute myeloid leukemia. Cell Mol Life Sci 70: 1307-1317, 2013.
61. Neri LM, Cani A, Martelli AM, Simioni C, Junghanss C, Tabellini G, Ricci F, Tazzari PL, Pagliaro P, McCubrey JA and Capitani S: Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia 28: 739-748, 2014.
62. Wang K, Liu R, Li J, Mao J, Lei Y, Wu J, Zeng J, Zhang T, Wu H, Chen L, et al: Quercetin induces protective autophagy in gastric cancer cells: Involvement of Akt-mTOR-and hypoxia-induced factor 1α-mediated signaling. Autophagy 7: 966-978, 2011.
63. Alayev A and Holz MK: mTOR signaling for biological control and cancer. J Cell Physiol 228: 1658-1664, 2013.